Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Stocks in this Quantisnow insightHealth Care
Historical context for LSTA
Across the 4 sessions after earlier LSTA headlines, the stock closed higher 2 times and lower 2 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LSTA | SPY |
|---|---|---|---|
| Nov 7, 2025 | Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | -12.3% | +0.1% |
| Nov 6, 2025 | Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year' | +0.4% | -1.1% |
| Nov 5, 2025 | Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent | -5.3% | +0.3% |
| Oct 30, 2025 | Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 | +0.4% | -1.1% |
Keep researching LSTA
Quantisnow market dataNASDAQ
LSTA
Lisata Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for LSTA
Full LSTA profile on Quantisnow Follow LSTA and get a push notification the moment its next story breaks.